triflusal profile

Triflusal is a non-steroidal anti-inflammatory drug (NSAID) with antiplatelet activity. It is used to prevent blood clots in people who have had a heart attack, stroke, or other circulatory problems. Triflusal is a prodrug that is converted to its active metabolite, salicylic acid, in the body. Triflusal inhibits platelet aggregation by irreversibly acetylating the platelet cyclooxygenase enzyme. This inhibition of cyclooxygenase prevents the formation of thromboxane A2, a potent platelet aggregator. Triflusal has been shown to reduce the risk of cardiovascular events, such as stroke and myocardial infarction, in patients with a history of cardiovascular disease. Triflusal is also being studied for its potential use in the prevention of Alzheimer's disease. Triflusal is generally well-tolerated, but it can cause gastrointestinal side effects such as heartburn, nausea, and ulcers. It can also increase the risk of bleeding. Triflusal should be used with caution in patients with a history of gastrointestinal bleeding, kidney disease, or liver disease.'

triflusal: inhibits platelet aggregation similarly to aspirin; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9458
CHEMBL ID	1332032
CHEBI ID	94721
SCHEMBL ID	136423
MeSH ID	M0065977

Synonym
AC-1829
PRESTWICK3_000528
triflux
disgren
ur-1501
tecnosal
BPBIO1_000567
BSPBIO_000515
einecs 206-297-5
2,4-cresotic acid, alpha,alpha,alpha-trifluoro-, acetate
3-acetoxy-alpha,alpha,alpha-trifluoro-p-toluic acid
c10h7f3o4
2-(acetyloxy)-4-(trifluoromethyl)benzoic acid
benzoic acid, 2-(acetyloxy)-4-(trifluoromethyl)-
brn 2945374
4-trifluoromethylsalicylic acid acetate
alpha,alpha,alpha-trifluoro-2,4-creosotic acid acetate
triflusalum [inn-latin]
2-acetoxy-4-trifluoromethylbenzoic acid
triflusal [inn]
alpha,alpha,alpha-trifluoro-2,4-cresotic acid acetate
ur 1501
triflusal
322-79-2
PRESTWICK_851
NCGC00016431-01
cas-322-79-2
triflusal (inn)
D07142
PRESTWICK2_000528
SPBIO_002436
PRESTWICK1_000528
PRESTWICK0_000528
NCGC00016431-02
2-acetyloxy-4-(trifluoromethyl)benzoic acid
HMS1569J17
A5797
2-acetoxy-4-trifluoromethyl-benzoic acid
HMS2096J17
triflusal [inn:ban]
grendis
unii-1z0yfi05oo
triflusalum
aflen
4-10-00-00619 (beilstein handbook reference)
1z0yfi05oo ,
dtxcid6025305
dtxsid8045305 ,
tox21_110436
S3200
FT-0601555
AKOS015890393
CHEMBL1332032
BRD-K71696703-001-01-2
2-acetoxy-4-(trifluoromethyl)benzoic acid
CCG-222319
CCG-220528
HY-B0531
SCHEMBL136423
MB01536
triflusal [mi]
triflusal [ep monograph]
triflusal [mart.]
triflusal [who-dd]
NCGC00016431-04
W-106849
drisgen
ur1501
SR-01000872666-1
sr-01000872666
CHEBI:94721
HMS3652M11
AS-63983
triflusal; 2-(acetyloxy)-4-(trifluoromethyl)benzoic acid
HMS3713J17
SW196982-3
DB08814
mfcd00866793
2-acetoxy-4-trifluoromethyl benzoic acid
T3601
acetyl-4-(trifluoromethyl)salicylic acid
BCP10024
Q1758668
NCGC00016431-11
HMS3885I13
T72290
EN300-18567716

Excerpt	Reference	Relevance
"Triflusal is a drug that inhibits platelet aggregation. "	( Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. Gwon, MR; Han, S; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, JG; Park, SM; Seong, SJ; Yang, DH; Yoon, YR, 2014)	2.06
"Triflusal is a 4-fluoromethyl derivative of salicylic acid used for secondary prevention of ischemic stroke. "	( Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke. Alvarez-Sabín, J; García-Bonilla, L; Krupinski, J; Montaner, J; Penalba, A; Quintana, M, 2009)	3.24
"Triflusal is a derivative of acetylsalicylic acid but it exhibits different pharmacological and pharmacokinetic properties. "	( Comparison of triple antiplatelet therapy including triflusal and conventional dual therapy in patients who underwent drug-eluting stent implantation. Kang, HJ; Kim, HS; Kim, SY; Kim, YS; Koo, BK; Park, JS; Suh, JW, 2009)	2.05
"Triflusal is an antiplatelet agent that irreversibly acetylates cyclooxygenase isoform 1 (COX-1) and therefore inhibits thromboxane biosynthesis. "	( Gastrointestinal safety of triflusal solution in healthy volunteers: a proof of concept endoscopic study. Antonijoan, RM; Azaro, A; Balanzó, J; Barbanoj, MJ; Blanch, I; Borja, J; Donado, E; Gich, I; Izquierdo, I; Sainz, S, 2011)	2.11
"Triflusal is an antiplatelet salicylate derivative with anti-inflammatory effects."	( Comparative effects of triflusal, S-adenosylmethionine, and dextromethorphan over intestinal ischemia/reperfusion injury. Alarcón-Galván, G; Cámara-Lemarroy, CR; Cordero-Pérez, P; Fernández-Garza, NE; Guzmán-de la Garza, FJ; Muñoz-Espinosa, LE; Torres-Gonzalez, L, 2011)	1.4
"Triflusal is an antiplatelet agent that has shown clinical advantages when compared with aspirin in the secondary prevention of vascular events. "	( Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Abiusi, G; Bauso-Tosselli, L; Culebras, A; Domínguez, R; Famulari, A; Ferrari, J; Gori, H; Reich, E; Rey, R; Rotta-Escalante, R; Vila, J, 2004)	3.21
"Triflusal is a fluorinated derivative of acetylsalicylic acid (ASA) with demonstrated antithrombotic activity. "	( Protective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids. Arrebola, MM; De La Cruz, JP; González-Correa, JA; Guerrero, A; Muñoz-Marín, J; Ruiz-Villafranca, D; Sánchez de la Cuesta, F; Ureña, IM, 2005)	2.09
"Triflusal is an antiplatelet drug related to aspirin, with different pharmacological properties and a lower haemorrhagic risk. "	( Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus. Avellone, G; Ballone, E; Ciabattoni, G; Davì, G; Di Febbo, C; Di Nicola, M; Falco, A; Pinto, A; Salvati, F; Vitacolonna, E, 2005)	2.04
"Triflusal is a derivative of salicylic acid with a well-established platelet aggregation inhibitory profile. "	( Triflusal: an antiplatelet drug with a neuroprotective effect? De La Cruz, JP; González-Correa, JA, 2006)	3.22
"Triflusal is a preferential COX-2 inhibitor antiplatelet agent that is as effective as aspirin in the prevention of serious vascular events."	( Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases. Borja, J; Fraj, J; Izquierdo, I; Pérez, I; Picado, C; Valero, A; Vives, R, 2008)	1.47
"Triflusal is an antiplatelet agent structurally related to the salicylate group of compounds, but it is not derived from aspirin (acetylsalicylic acid). "	( Triflusal. Goa, KL; McNeely, W, 1998)	3.19
"Triflusal is a fluorinated aspirin derivative with antiplatelet properties, which is used in Spain for the management and prevention of thromboembolic disease."	( Photosensitivity associated with treatment with triflusal. Aliaga, A; Nagore, E; Pérez-Ferriols, A; Sánchez-Motilla, JM; Serrano, G, 2000)	2.01
"Triflusal is a platelet antiaggregant drug with photoallergic side effects. "	( Photochemistry of 2-hydroxy-4-trifluoromethylbenzoic acid, major metabolite of the photosensitizing platelet antiaggregant drug triflusal. Boscá, F; Cuquerella, MC; Marín, ML; Miranda, MA, 2001)	1.96
"Triflusal is an irreversible inhibitor of platelet cyclooxygenase. "	( Compliance of geriatric patients subjected to antiplatelet agents with Triflusal in peripheral arteriopathy. Preliminary data. Apostolou, D; Comelli, S; Maselli, M; Moniaci, D; Ortensio, M; Scovazzi, P; Varetto, G; Zan, S, 2002)	1.99
"Triflusal is a new antithrombotic agent, structurally similar to acetylsalicylic acid (ASA), which has been shown to possess a different pharmacological profile, suggesting a different mechanism of action for both compounds. "	( Comparison of the inhibitory effects of acetylsalicylic acid and trifusal on enzymes related to thrombosis. Garcia Rafanell, J; Planas, JM; Puig-Parellada, P, 1979)	1.7
"1. Triflusal is a salicylic derivative that inhibits platelet aggregation in human whole blood with a minimal inhibition of prostacyclin production. "	( Triflusal vs aspirin on the inhibition of human platelet and vascular cyclooxygenase. de la Cruz, JP; Mata, JM; Sanchez de la Cuesta, F, 1992)	2.35
"Triflusal (TR) is a new salicylic acid derivative used clinically as an antiplatelet drug. "	( Effects and interaction studies of triflusal and other salicylic derivatives on cyclooxygenase in rats. Albors, M; De Castellarnau, C; Rutllant, ML; Sancho, MJ; Vila, L, 1988)	1.99

Excerpt	Reference	Relevance
"Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events."	( Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial. Adamopoulos, D; Asimakopoulos, C; Bourdakis, A; Chantzichristos, VG; Darmanis, P; Dimitriadou, A; Gkiokas, S; Goudevenos, JA; Ipeirotis, K; Kalantzi, KI; Kitikidou, K; Klonaris, I; Kostaki, A; Logothetis, D; Mainas, K; Mais, T; Maragiannis, A; Martiadou, K; Mavronasos, K; Michelongonas, I; Mitropoulos, D; Ntalas, IV; Panagiotakos, DB; Papadimitriou, G; Papadopoulos, A; Papaioakeim, M; Sofillas, K; Stabola, S; Stefanakis, E; Stergiou, D; Thoma, M; Tselepis, AD; Tsoumani, ME; Zenetos, A; Zisekas, S, 2019)	2.32
"Triflusal has been shown to exert neuroprotective effects by downregulating molecules considered responsible for the development of Alzheimer's disease (AD). "	( Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. Barbanoj, MJ; Brunner, M; Donner, A; Eichler, HG; Herranz, U; Izquierdo, I; Klein, N; Müller, M; Valle, M, 2005)	2.05

Excerpt	Reference	Relevance
"Triflusal displays a Cmax of 11.6 +/- 1.7 micrograms/ml and a tmax of 0.88 +/- 0.26 h."	( Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Forn, J; Gorina, E; Jané, F; Mis, R; Ramis, J; Torrent, J, )	1.18

Excerpt	Reference	Relevance
"Triflusal treatment did not alter the total brain Abeta accumulation but significantly reduced dense-cored plaque load and associated glial cell proliferation, proinflammatory cytokine levels and abnormal axonal curvature, and rescued cognitive deficits in Tg2576 mice."	( Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Agulló, J; Bacskai, BJ; Borrelli, LA; Clarimón, J; Coma, M; Da Rocha-Souto, B; España, J; Garcia-Alloza, M; Gómez-Isla, T; Guardia-Laguarta, C; Hyman, BT; Lleó, A; Rodríguez, M; Sánchez, MB; Saura, CA; Scotton, TC; Serenó, L, 2010)	2.52
"Triflusal posttreatment diminishes glial NF-kappaB, downregulates the glial response, and improves the lesion outcome, suggesting a neuroprotective role of this compound against excitotoxic injury in the immature brain."	( Triflusal posttreatment inhibits glial nuclear factor-kappaB, downregulates the glial response, and is neuroprotective in an excitotoxic injury model in postnatal brain. Acarin, L; Castellano, B; González, B, 2001)	3.2

Excerpt	Reference	Relevance
"Low-dose aspirin (acetylsalicylic acid) has been shown to be as effective as high-dose aspirin in the prevention of stroke, with fewer adverse bleeding events."	( Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. Weinberger, J, 2005)	0.33
"An enteric-coated formulation of triflusal (triflusal EC), an antiplatelet agent, was developed to reduce the high incidence of gastrointestinal adverse events (AEs)."	( A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers. Baek, IH; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, J; Seo, JJ; Seong, SJ; Yoon, YR; Yun, HY, 2011)	0.86
" Safety was assessed by adverse events, ECG, laboratory testing, and vital signs."	( Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. Hua, W; Huang, M; Wang, M; Zhang, Q; Zhou, W; Zong, S, 2014)	0.66

Excerpt	Reference	Relevance
" In the present study, we have developed a new analytical technique based on HPLC that enabled us to carry out a pharmacokinetic study of the drug and its metabolite in animals."	( Pharmacokinetics of triflusal and its main metabolite in rats and dogs. Forn, J; Mis, R; Ramis, J, )	0.45
"The pharmacokinetic profile of triflusal (2-acetoxy-4-trifluoromethyl benzoic acid) and its main metabolite HTB (2-hydroxy-4-trifluoromethyl benzoic acid) has been studied in 8 healthy subjects (4 males and 4 females), after a single oral dose of 900 mg of triflusal."	( Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Forn, J; Gorina, E; Jané, F; Mis, R; Ramis, J; Torrent, J, )	0.74
" No significant differences were observed between the elimination half-life obtained after the single dose and after the two repeated dose regimens studied."	( Pharmacokinetics of triflusal after single and repeated doses in man. Barbanoj, MJ; Conte, L; Forn, J; Jané, J; Mis, R; Ramis, J; Torrent, J, 1990)	0.6
"The pharmacokinetic and pharmacodynamic profiles of the two triflusal formulations met the requirements for bioequivalence and non-inferiority, respectively."	( A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers. Baek, IH; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, J; Seo, JJ; Seong, SJ; Yoon, YR; Yun, HY, 2011)	0.82
" In this study we investigated the dose-exposure-response relationship of a triflusal formulation by population pharmacokinetic (PK) and pharmacodynamic (PD) modeling of its main active metabolite, hydroxy-4-(trifluoromethyl) benzoic acid (HTB)."	( Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. Gwon, MR; Han, S; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, JG; Park, SM; Seong, SJ; Yang, DH; Yoon, YR, 2014)	0.85
"The objective of this study was to evaluate the pharmacokinetic parameters of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid (HTB), following a single oral dose of 900 mg in healthy subjects under fed and fasting conditions."	( Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. Ding, LK; Ding, Y; Ge, J; Jia, YY; Lu, CT; Song, W; Song, Y; Wen, AD; Yang, J, 2015)	0.91
"The mean Cmax of triflusal and HTB were 13."	( Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. Ding, LK; Ding, Y; Ge, J; Jia, YY; Lu, CT; Song, W; Song, Y; Wen, AD; Yang, J, 2015)	1.02

Excerpt	Reference	Relevance
" The bioavailability of triflusal in rats was only 10."	( Pharmacokinetics of triflusal and its main metabolite in rats and dogs. Forn, J; Mis, R; Ramis, J, )	0.76
" The purpose of this clinical trial was to study the relative bioavailability of the new oral solution of triflusal versus the capsules formulation, both administered as a single dose."	( Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study. Borja, J; Cebrecos, J; García-Rafanell, J; Izquierdo, I; Pelagio, P; Rovira, S; Torres, F, 2010)	0.85
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
"ss) during the multiple dosage regimen of 300 mg every 8 h, and 131 micrograms."	( Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man. Conte, L; Forn, J; Mis, R; Ramis, J, 1992)	0.58
"Triflusal pharmacokinetics were evaluated in 8 healthy subjects after a single 300 mg dose and after repeated doses of 300 mg every 8 h and 600 mg every 24 h during 13 days, with the aim of establishing a relationship between plasma levels and dosage patterns."	( Pharmacokinetics of triflusal after single and repeated doses in man. Barbanoj, MJ; Conte, L; Forn, J; Jané, J; Mis, R; Ramis, J; Torrent, J, 1990)	2.05
"Following oral dosing under fasting condition, triflusal is promptly absorbed and rapidly depleted from the systemic circulation."	( Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects. Hua, W; Huang, M; Wang, M; Zhang, Q; Zhou, W; Zong, S, 2014)	0.92
"The time-concentration profile of HTB over the entire dosing period was described by a one-compartment model with a first-order formation rate constant for HTB."	( Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study. Gwon, MR; Han, S; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, JG; Park, SM; Seong, SJ; Yang, DH; Yoon, YR, 2014)	0.62
" Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazodone, significantly elevated FGF20 levels in the nigrostriatal tract."	( Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats. Doherty, P; Duty, S; Fletcher, EJR; Jamieson, AD; Williams, G, 2019)	0.76

Class	Description
salicylates	Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.
carboxylic ester	An ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl.
benzoic acids	Any aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, HADH2 protein	Homo sapiens (human)	Potency	12.5893	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	12.5893	0.0251	20.2376	39.8107	AID893
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	15.8489	0.1778	14.3909	39.8107	AID2147
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	15.8489	0.0112	12.4002	100.0000	AID1030
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	9.5221	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C19 precursor	Homo sapiens (human)	Potency	3.9811	0.0025	5.8400	31.6228	AID899
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	14.1254	0.0018	15.6638	39.8107	AID894
ubiquitin carboxyl-terminal hydrolase 2 isoform a	Homo sapiens (human)	Potency	5.0119	0.6561	9.4520	25.1189	AID927
Interferon beta	Homo sapiens (human)	Potency	21.3174	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)	Potency	5.0119	1.5849	13.0043	25.1189	AID927
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	21.3174	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to hypoxia	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
neutrophil mediated immunity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
germinal center formation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of leukocyte chemotaxis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
proteolysis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane protein ectodomain proteolysis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell adhesion	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch receptor processing	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell population proliferation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to xenobiotic stimulus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of T cell chemotaxis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein processing	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
signal release	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
B cell differentiation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell growth	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell migration	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to lipopolysaccharide	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of chemokine production	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
regulation of mast cell apoptotic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
T cell differentiation in thymus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell adhesion mediated by integrin	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
wound healing, spreading of epidermal cells	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
amyloid precursor protein catabolic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
spleen development	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell motility	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
defense response to Gram-positive bacterium	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cellular response to high density lipoprotein particle stimulus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
commissural neuron axon guidance	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
interleukin-6 receptor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
integrin binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
peptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metallopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
SH3 domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytokine binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
PDZ domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
tumor necrosis factor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metal ion binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell-cell junction	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
focal adhesion	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
ruffle membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Golgi membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytoplasm	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
endoplasmic reticulum lumen	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytosol	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell surface	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
actin cytoskeleton	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
apical plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane raft	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1136196	Antiinflammatory activity against carrageenan-induced foot edema in rat administered via gastric gavage	1978	Journal of medicinal chemistry, Nov, Volume: 21, Issue:11	Novel analgesic-antiinflammatory salicylates.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	24 (16.33)	18.7374
1990's	25 (17.01)	18.2507
2000's	55 (37.41)	29.6817
2010's	37 (25.17)	24.3611
2020's	6 (4.08)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	39 (23.78%)	5.53%
Reviews	11 (6.71%)	6.00%
Case Studies	9 (5.49%)	4.05%
Observational	1 (0.61%)	0.25%
Other	104 (63.41%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Randomized Placebo Controlled Phase II Cross Over Study on the Influence of Triflusal on Cognitive Functions in Healthy Participants [NCT02321852]	Phase 2	40 participants (Actual)	Interventional	2015-01-31	Completed
Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping [NCT01174693]	Phase 4	795 participants (Actual)	Interventional	2010-03-31	Completed
Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events [NCT02616497]	Phase 4	1,220 participants (Actual)	Interventional	2015-09-30	Completed
Randomized Placebo Controlled Phase II Cross Over Study on the Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress [NCT02904109]	Phase 2	41 participants (Actual)	Interventional	2016-09-13	Completed
Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity [NCT00162799]	Phase 2	30 participants	Interventional	2002-07-31	Completed
The Effect of Triflusal on Peripheral Microcirculation Dysfunction: A Double-Blind, Randomized, Controlled, Crossover Study. [NCT01612273]	Phase 4	92 participants (Actual)	Interventional	2011-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
bromide Bromides: Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)	2.02	1	0	halide anion; monoatomic bromine
salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).	3.23	6	0	monohydroxybenzoic acid	algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.11	1	0	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.	2.02	1	0	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
toluene methylbenzene : Any alkylbenzene that is benzene substituted with one or more methyl groups.	2.02	1	0	methylbenzene; toluenes; volatile organic compound	cholinergic antagonist; fuel additive; neurotoxin; non-polar solvent
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	2.21	1	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	13.84	57	14	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
cilostazol [no description available]	2.1	1	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	1.95	1	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
dimethadione Dimethadione: An anticonvulsant that is the active metabolite of TRIMETHADIONE.	2.21	1	0	oxazolidinone
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	7.03	10	1	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	7.11	1	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fosfosal fosfosal: reagent for testing the activity of certain enzymes	1.96	1	0	aryl phosphate
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	1.95	1	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	1.95	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
oxidopamine Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).	2.21	1	0	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
propidium Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.	2.05	1	0	phenanthridines; quaternary ammonium ion	fluorochrome; intercalator
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	7.9	9	1	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
trazodone Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.	2.21	1	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	7.05	1	0	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	4.84	4	2	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	2	1	0	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
methacrylamide [no description available]	2.02	1	0	acrylamides; primary carboxamide
dodecyltrimethylammonium dodecyltrimethylammonium: used to determine thermal stability of DNA; RN given refers to parent cpd. dodecyltrimethylammonium ion : A quarternary ammonium cation having one dodecyl and three methyl substituents around the central nitrogen.	2.03	1	0	quaternary ammonium ion
3-phenylsalicylic acid 3-phenylsalicylic acid: structure given in first source	1.95	1	0
citrulline citrulline : The parent compound of the citrulline class consisting of ornithine having a carbamoyl group at the N(5)-position.	2	1	0	amino acid zwitterion; citrulline	Daphnia magna metabolite; EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; protective agent; Saccharomyces cerevisiae metabolite
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.06	1	0	dialdehyde	biomarker
sodium hydroxide Sodium Hydroxide: A highly caustic substance that is used to neutralize acids and make sodium salts. (From Merck Index, 11th ed)	2.03	1	0	alkali metal hydroxide
n-methylaspartate N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.	2.41	2	0	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	8.47	1	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
clopidogrel Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.	12.82	8	1	methyl ester; monochlorobenzenes; thienopyridine	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
5-fluorosalicylic acid 5-fluorosalicylic acid: structure given in first source; product from action of alkaline phosphatase on 5-fluorosalicyl phosphate; forms highly fluorescent terbium ternary complex	1.95	1	0
zwittergent 3-12 zwittergent 3-12: zwitterionic detergent. lauryl sulfobetaine : An ammonium betaine in which the ammonium nitrogen is substituted by dodecyl, 3-sulfatopropyl and two methyl groups.	2.03	1	0	ammonium betaine	detergent
4-trifluoromethylsalicylic acid 4-trifluoromethylsalicylic acid: structure given in first source; metabolite of triflusal	8.21	24	5	hydroxybenzoic acid
potassium bromide potassium bromide : A metal bromide salt with a K(+) counterion.	2.02	1	0	potassium salt
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	5.03	5	2	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	1.95	1	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.	2.03	1	0	organic sodium salt	detergent; protein denaturant
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.69	3	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
alprostadil [no description available]	2.37	2	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
6-ketoprostaglandin f1 alpha 6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.	4.27	4	1	prostaglandins Falpha	human metabolite; mouse metabolite
6-ketoprostaglandin e1 6-ketoprostaglandin E1: potent direct dilator of pulmonary & systemic circulations of newborn lamb. 6-oxoprostaglandin E1 : A prostaglandin E that is prostaglandin E1 bearing a keto substituent at the 6-position.	1.97	1	0	prostaglandins E	metabolite; platelet aggregation inhibitor
11-dehydro-thromboxane b2 11-dehydro-thromboxane B2: structure given in first source. 11-dehydro-thromboxane B2 : A thromboxane obtained by formal oxidation of the hemiacetal hydroxy function of thromboxane B2.	3.41	1	1	thromboxane	human metabolite
prostaglandin f1 prostaglandin F1: was EN to PROSTAGLANDINS F (75-81); RN given refers to (9 alpha,11 alpha,13E,15S)-isomer	1.97	1	0	prostaglandins Falpha	human metabolite
thromboxane b2 Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.	5.67	7	3	thromboxanes B	human metabolite; mouse metabolite
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	8.7	3	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	7.06	1	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
boron Boron: A trace element with the atomic symbol B, atomic number 5, and atomic weight [10.806; 10.821]. Boron-10, an isotope of boron, is used as a neutron absorber in BORON NEUTRON CAPTURE THERAPY.	7.05	1	0	boron group element atom; metalloid atom; nonmetal atom	micronutrient
3-trifluoromethylbenzoate 3-trifluoromethylbenzoate: RN given refers to unlabeled parent cpd	2.02	1	0
terutroban terutroban: a thromboxan receptor antagonist	3.17	1	0
prasugrel hydrochloride Prasugrel Hydrochloride: A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.. prasugrel hydrochloride : A racemate comprising equal amounts of (R)- and (S)-prasugrel hydrochloride. Used to prevent blood clots in people with acute coronary syndrome who are undergoing a procedure after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.	2.15	1	0
indocyanine green Indocyanine Green: A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output.	3.5	1	1	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	2.05	1	0
s-adenosylmethionine (R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine.	7.06	1	0	organic cation; sulfonium compound	coenzyme; cofactor; human metabolite; micronutrient; Mycoplasma genitalium metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
salicylates Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.	16.85	138	38	monohydroxybenzoate	plant metabolite
acenocoumarol Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233). acenocoumarol : A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group.	7.54	6	4	C-nitro compound; hydroxycoumarin; methyl ketone	anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	3.81	3	0	benzenes; hydroxycoumarin; methyl ketone
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2	1	0
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	2.4	2	0	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
guanosine monophosphate Guanosine Monophosphate: A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature.. guanosine 5'-monophosphate : A purine ribonucleoside 5'-monophosphate having guanine as the nucleobase.	2	1	0	guanosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	biomarker; Escherichia coli metabolite; metabolite; mouse metabolite

Condition	Indicated	Relationship Strength	Studies	Trials
Encephalitis, Polio [description not available]	0	2.06	1	0
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	0	2.06	1	0
Plasmodium falciparum Malaria [description not available]	0	2.1	1	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	0	2.1	1	0
Anemia, Fanconi [description not available]	0	2.13	1	0
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	0	2.13	1	0
Actinic Reticuloid Syndrome [description not available]	0	3.14	5	0
Neointima The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.	0	3.23	1	0
Acute Coronary Syndrome An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.	0	7.31	1	0
Allergy, Drug [description not available]	0	4.4	4	1
Heart Disease, Ischemic [description not available]	0	4.89	4	2
Graft Occlusion, Vascular Obstruction of flow in biological or prosthetic vascular grafts.	0	2.17	1	0
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	0	4.4	4	1
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	0	4.89	4	2
Cerebral Infarction, Middle Cerebral Artery [description not available]	0	2.57	2	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.82	11	0
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	0	2.57	2	0
Recrudescence [description not available]	0	9.22	9	6
Apoplexy [description not available]	0	11.17	15	5
Brain Emboli [description not available]	0	8.04	5	5
Cerebral Ischemia [description not available]	0	7.99	11	5
Arteriosclerosis, Coronary [description not available]	0	5.63	3	2
Bleeding [description not available]	0	10.07	9	8
Cardiovascular Stroke [description not available]	0	10.59	11	6
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	0	12.99	11	5
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	0	5.63	3	2
Hemorrhage Bleeding or escape of blood from a vessel.	0	15.07	9	8
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	0	10.59	11	6
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	11.17	15	5
Colorectal Cancer [description not available]	0	2.21	1	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	0	2.21	1	0
Idiopathic Parkinson Disease [description not available]	0	2.21	1	0
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	0	2.21	1	0
Blood Clot [description not available]	0	5.16	11	1
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	1	7.16	11	1
Coronary Restenosis Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.	0	3.85	2	1
Anterior Circulation Transient Ischemic Attack [description not available]	0	7.38	5	2
Indigestion [description not available]	0	3.48	1	1
Cerebral Arteriosclerosis [description not available]	0	3.48	1	1
Intracranial Arteriosclerosis Vascular diseases characterized by thickening and hardening of the walls of ARTERIES inside the SKULL. There are three subtypes: (1) atherosclerosis with fatty deposits in the ARTERIAL INTIMA; (2) Monckeberg's sclerosis with calcium deposits in the media and (3) arteriolosclerosis involving the small caliber arteries. Clinical signs include HEADACHE; CONFUSION; transient blindness (AMAUROSIS FUGAX); speech impairment; and HEMIPARESIS.	0	3.48	1	1
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	0	7.38	5	2
Dyspepsia Impaired digestion, especially after eating.	0	3.48	1	1
Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.	0	3.79	2	1
Atopic Hypersensitivity [description not available]	0	2.1	1	0
Dermatoses [description not available]	0	2.1	1	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	0	2.1	1	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	0	7.54	4	3
Hives [description not available]	0	2.13	1	0
Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.	0	11.95	6	1
Urticaria A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.	0	2.13	1	0
Brain Hemorrhage, Cerebral [description not available]	0	5.01	3	1
Cerebral Hemorrhage Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.	0	5.01	3	1
Facial Dermatoses Skin diseases involving the FACE.	0	2.13	1	0
Coronary Heart Disease [description not available]	0	2.15	1	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	0	2.15	1	0
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	0	2.05	1	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	0	7.39	2	0
Dermatitis, Contact, Photoallergic [description not available]	0	2.43	2	0
Auricular Fibrillation [description not available]	0	9.55	10	5
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	0	14.55	10	5
Amyloid Deposits [description not available]	0	2.05	1	0
Acute Confusional Senile Dementia [description not available]	0	2.96	4	0
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	0	2.46	2	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	0	2.96	4	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	0	2.05	1	0
Innate Inflammatory Response [description not available]	0	2.71	3	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	7.71	3	0
Injury, Ischemia-Reperfusion [description not available]	0	2.44	2	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	0	7.44	2	0
Embolus [description not available]	0	7.83	5	5
Embolism Blocking of a blood vessel by an embolus which can be a blood clot or other undissolved material in the blood stream.	0	7.83	5	5
Degenerative Diseases, Central Nervous System [description not available]	0	2.01	1	0
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	0	2.01	1	0
Anterior Choroidal Artery Infarction [description not available]	0	8.29	6	2
Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).	0	8.29	6	2
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.01	1	0
Rheumatoid Arthritis [description not available]	0	2.01	1	0
Click-Murmur Syndrome [description not available]	0	2.01	1	0
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	0	2.01	1	0
Anoxemia [description not available]	0	2.02	1	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	0	2.02	1	0
Dermatitis Medicamentosa [description not available]	0	2.41	2	0
Diabetes Mellitus, Adult-Onset [description not available]	0	3.81	2	1
Dermatitis, Eczematous [description not available]	0	2.02	1	0
Elevated Cholesterol [description not available]	0	2.02	1	0
Blood Pressure, High [description not available]	0	2.02	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	0	3.81	2	1
Eczema A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents (Dorland, 27th ed).	0	7.02	1	0
Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.	0	2.02	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	2.02	1	0
Mitral Stenosis [description not available]	0	7.63	5	4
Mitral Valve Stenosis Narrowing of the passage through the MITRAL VALVE due to FIBROSIS, and CALCINOSIS in the leaflets and chordal areas. This elevates the left atrial pressure which, in turn, raises pulmonary venous and capillary pressure leading to bouts of DYSPNEA and TACHYCARDIA during physical exertion. RHEUMATIC FEVER is its primary cause.	0	7.63	5	4
Anoxia, Brain [description not available]	0	2.02	1	0
Brain Vascular Disorders [description not available]	0	5.95	5	2
Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	0	5.95	5	2
Blood Loss, Postoperative [description not available]	0	4.32	1	1
Heart Valve Diseases Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).	0	4.32	1	1
Complication, Postoperative [description not available]	0	6.68	4	2
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	0	6.68	4	2
Cardiac Hypertrophy Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.	0	7.03	1	0
Cardiomegaly Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.	0	2.03	1	0
Cardiac Arrest, Sudden [description not available]	0	2.03	1	0
Death, Sudden, Cardiac Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)	0	2.03	1	0
Asthma, Bronchial [description not available]	0	3.43	1	1
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	0	3.43	1	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	0	3.43	1	1
Disease, Pulmonary [description not available]	0	2.36	2	0
Lung Diseases Pathological processes involving any part of the LUNG.	0	2.36	2	0
Intertrochanteric Fractures [description not available]	0	3.37	1	1
Embolism, Pulmonary [description not available]	0	4.7	2	1
Phlegmasia Alba Dolens Inflammation that is characterized by swollen, pale, and painful limb. It is usually caused by DEEP VEIN THROMBOSIS in a FEMORAL VEIN, following PARTURITION or an illness. This condition is also called milk leg or white leg.	0	4.7	2	1
Emesis [description not available]	0	3.37	1	1
Hip Fractures Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).	0	3.37	1	1
Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.	0	4.7	2	1
Thrombophlebitis Inflammation of a vein associated with a blood clot (THROMBUS).	0	4.7	2	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	0	3.37	1	1
Complications of Diabetes Mellitus [description not available]	0	3.37	1	1
Angina at Rest [description not available]	0	4.33	2	2
Angina, Unstable Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.	0	4.33	2	2
Thrombocytopathy [description not available]	0	3.37	1	1
Blood Platelet Disorders Disorders caused by abnormalities in platelet count or function.	0	3.37	1	1
Brain Damage, Chronic A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.	0	1.98	1	0
Brain Embolism and Thrombosis [description not available]	0	2.38	2	0
Chronic Illness [description not available]	0	3.37	1	1
Diseases, Peripheral Vascular [description not available]	0	3.37	1	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	3.37	1	1
Peripheral Vascular Diseases Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.	0	3.37	1	1
Acute Onset Vascular Dementia [description not available]	0	3.38	1	1
Dementia, Vascular An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)	0	3.38	1	1
Angor Pectoris [description not available]	0	2.91	1	0
Carotid Artery Narrowing [description not available]	0	2.91	1	0
Angina Pectoris The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.	0	2.91	1	0
Carotid Stenosis Narrowing or stricture of any part of the CAROTID ARTERIES, most often due to atherosclerotic plaque formation. Ulcerations may form in atherosclerotic plaques and induce THROMBUS formation. Platelet or cholesterol emboli may arise from stenotic carotid lesions and induce a TRANSIENT ISCHEMIC ATTACK; CEREBROVASCULAR ACCIDENT; or temporary blindness (AMAUROSIS FUGAX). (From Adams et al., Principles of Neurology, 6th ed, pp 822-3)	0	2.91	1	0
Disease Exacerbation [description not available]	0	3.38	1	1
Arterial Diseases, Carotid [description not available]	0	3.38	1	1
Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.	0	8.38	1	1
Carotid Artery Diseases Pathological conditions involving the CAROTID ARTERIES, including the common, internal, and external carotid arteries. ATHEROSCLEROSIS and TRAUMA are relatively frequent causes of carotid artery pathology.	0	3.38	1	1
Cardiac Diseases [description not available]	0	2	1	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	0	2	1	0
Anaplastic Astrocytoma [description not available]	0	2	1	0
Benign Neoplasms, Brain [description not available]	0	2	1	0
Astrocytoma Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)	0	2	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	2	1	0
Acute Disease Disease having a short and relatively severe course.	0	3.39	1	1
Arterial Obstructive Diseases [description not available]	0	2.01	1	0
Arterial Occlusive Diseases Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.	0	2.01	1	0
Respiration Disorders Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.	0	1.95	1	0
Autoimmune Diabetes [description not available]	0	4.05	3	1
Albuminuria The presence of albumin in the urine, an indicator of KIDNEY DISEASES.	0	1.97	1	0
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	0	4.05	3	1
Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.	0	3.76	2	1

triflusal

Description

Cross-References

Synonyms (87)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Drug Classes (3)

Protein Targets (14)

Potency Measurements

Biological Processes (82)

Molecular Functions (31)

Ceullar Components (29)

Bioassays (11)

Research

Studies (147)

Market Indicators

Research Demand Index: 56.41

Study Types

Clinical Trials (6)

Trial Overview

triflusal

Description

Cross-References

Synonyms (87)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Drug Classes (3)

Protein Targets (14)

Potency Measurements

Biological Processes (82)

Molecular Functions (31)

Ceullar Components (29)

Bioassays (11)

Research

Studies (147)

Market Indicators

Research Demand Index: 56.41

Study Types

Clinical Trials (6)

Trial Overview

Related Drugs (60)

Related Conditions (151)